RELATED PARTY TRANSACTIONS |
9 Months Ended | ||
|---|---|---|---|
Sep. 30, 2021 | |||
| RELATED PARTY TRANSACTIONS [Abstract] | |||
| RELATED PARTY TRANSACTIONS |
The Company leases an office building and equipment from Areth, LLC (“Areth”)
pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time. Rent expense for the nine months ended September 30, 2021 and 2020 amounted to $90,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company’s Board of Directors, and Adam S. Grossman, the Company’s President and
Chief Executive Officer. The Company also reimburses Areth for office and building-related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the nine
months ended September 30, 2021 and 2020. In addition, during the nine months ended September 30, 2021 and 2020, the Company purchased certain specialized medical equipment and services related to the Company’s plasma collection centers, as well as
personal protective equipment, from GenesisBPS and its affiliates (“Genesis”), in the amount of $0.1 million. Dr. Grossman and Adam
Grossman each own shares of Genesis.
See Note 7 for a discussion of the Company’s credit facility and related
transactions with Perceptive, a holder of approximately 9.6% of the Company’s common stock.
During the nine months ended September 30, 2021, in connection with the resignation
of Dr. James Mond, the Company’s former Chief Scientific and Medical Officer, the Company recognized an expense and corresponding liability in the amount of $0.8 million for estimated payments to be made under a separation and transition agreement with Dr. Mond. Such payments are to be made in scheduled installments over a period of 10 months.
In connection with the February 2020 public offering of the Company’s common stock
(see Note 8) on February 11, 2020: (i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock
through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls, (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls, (v)
Brian Lenz, the Company’s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) Dr.
Mond purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.
|